Navigation Links
Isis Reports Financial Results and Highlights for 2012
Date:2/28/2013

otes, and an increase in interest expense.  Isis' interest expense was higher than in 2011 due to additional non-cash interest expense Isis recorded for the long-term liability associated with its primary research and development facility and slightly higher interest expense related to Isis' 2 ¾%  Notes.

Balance Sheet
As of December 31, 2012, Isis had cash, cash equivalents and short-term investments of $374.4 million compared to $343.7 million at December 31, 2011 and had working capital of $349.1 million at December 31, 2012 compared to $284.0 million at December 31, 2011. During 2012, Isis received a substantial amount of cash, including $96 million in upfront payments from Biogen Idec and AstraZeneca, a $25 million milestone payment from Genzyme for FDA acceptance of the KYNAMRO NDA and approximately $30 million in net proceeds from Isis' issuance of its 2 ¾% Notes.  Isis' working capital increased significantly in 2012 primarily due to the cash Isis received in 2012 and an increase in current assets resulting from Isis' investment in Regulus because Isis is now recording its investment at fair value. At December 31, 2012, the carrying value of Isis' investment in Regulus was $33.6 million.

2013 Goals
"We expect 2013 to be a year of substantial growth and maturation for Isis.  We believe that the initial commercial launch of KYNAMRO will be successful and we support Genzyme's ongoing development efforts for KYNAMRO with the FOCUS FH study, which Genzyme is conducting under a special protocol assessment with the FDA," continued Ms. Parshall.  "Beyond KYNAMRO, we have a number of drugs in our pipeline that will complete later-stage clinical studies, which are designed to provide clear evidence that these drugs have the potential to work in patients in numerous different diseases.  In addition, we plan to advance many other drugs in our pipeline, creating additional opportunities for significant lon
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
2. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
3. Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65
4. HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
5. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
6. Kewaunee Scientific Reports Improved Results for Third Quarter
7. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
8. Questcor Reports Fourth Quarter and Full Year 2012 Results
9. ResearchMoz: Global MRI Systems Market to 2018 - Technological Advancements, Increasing Number of Applications and Advent of MRI Compatible Pacemakers to Drive Future Growth - Market Research Reports
10. United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
11. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Inc. (NASDAQ: CPIX ), a specialty ... gastroenterology, today announced fourth quarter and annual 2014 ... 2014 to $37 million, resulting in Adjusted Earnings ... At the end of 2014, Cumberland had total ... in cash and investments, with no debt. ...
(Date:3/3/2015)... , March 3, 2015   Surefire Medical, ... prospective clinical trial comparing the Surefire Infusion System with ... primary or metastatic liver cancer, using the Surefire ... of embolic agents, and with significantly decreased uptake ... today at the Society of Interventional Radiology ...
(Date:3/3/2015)... AUSTIN, Texas , March 3, 2015  UnaliWear ... that provides advanced support for seniors that guards against ... The new wearable – the Kanega ... of its kind to use an easy speech interface ... update medical information without human input. ...
Breaking Medicine Technology:Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 2Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 3Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 4Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 5Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 6Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 7Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 8Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 9Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 10Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 11Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 12Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 13Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 14Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 15Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 16Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 17Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 18Clinical Trial Comparing the Surefire Infusion Device to an End Hole Catheter Finds Surefire Increases Tumor Uptake and Decreases Non-Target Embolization In Every Patient, Multiple Liver Cancer Types 2UnaliWear's Wearable For Seniors Extends Independence With Advanced Technology 2
... WIRE)--Mar 19, 2007 - Acorda,Therapeutics (Nasdaq: ACOR) today ... Sclerosis Center at the University,of Rochester, will present ... Fampridine-SR in multiple sclerosis at the,upcoming American Academy ... place on Wednesday May 2, 2007 at 4:15 ...
... 2007 - Nymox,Pharmaceutical Corporation (NASDAQ: NYMX) today ... outcome study of NX-1207,for benign prostatic hyperplasia ... and 116 unselected subjects participated in the,blinded, ... scores and treatment outcome 8-19,months after NX-1207 ...
Cached Medicine Technology:Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data,Selected for Scientific Highlights Program at the American Academy,of Neurology Meeting 2Nymox Announces Positive Results from Newly Completed Long-term,Study of NX-1207 for Benign Prostatic Hyperplasia 2Nymox Announces Positive Results from Newly Completed Long-term,Study of NX-1207 for Benign Prostatic Hyperplasia 3
(Date:3/4/2015)... (PRWEB) March 04, 2015 The week ... Awareness Week with World Sleep Awareness Day being recognized ... to the health and financial risks associated with sleep ... the Sleep Apnea Treatment Centers of America have turned ... educational articles, they hope will virally inspire conversation regarding ...
(Date:3/4/2015)... Alexandria, VA (PRWEB) March 04, 2015 ... had surprising results. When asked —“What retirement cost ... many respondents said healthcare and prescription costs were most ... and utilities, another 40%. Sixteen percent said nourishing ... cost. , “This poll is important because it illustrates ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Follow ... worrisome public health issue worldwide. The rising prevalence of ... and social burden in both developed and developing countries. ... projected to rise to 1.5 billion, equating to approximately ... these patients are forecast to come from the developing ...
(Date:3/4/2015)... 2015 Theme and plugin developers from ... for Final Cut Pro X entitled ProFont NoteBook , “ProFont ... any FCPX editors project.” Said Christiana Austin, CEO of Pixel ... add animated font to their FCPX media.” , With ProFont ... within Final Cut Pro X. ProFont Notebook offers users up ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Bird B ... industrial and residential applications now offers its popular plastic ... The humane, highly efficient bird deterrent is ... match the color and décor of the building or ... colors—brick red, white, crystal clear, light grey, brown, black ...
Breaking Medicine News(10 mins):Health News:Innovative Sleep Apnea Procedure Could Save US Healthcare System Billions 2Health News:Innovative Sleep Apnea Procedure Could Save US Healthcare System Billions 3Health News:Innovative Sleep Apnea Procedure Could Save US Healthcare System Billions 4Health News:Most Difficult Cost In Retirement? Retirees Evenly Split Between Housing and Healthcare, Says New Poll By The Senior Citizens League 2Health News:Aging Population Drives Demand for Blood Pressure Monitoring & Measurement Instruments, According to a New Report by Global Industry Analysts, Inc. 2Health News:Aging Population Drives Demand for Blood Pressure Monitoring & Measurement Instruments, According to a New Report by Global Industry Analysts, Inc. 3Health News:Aging Population Drives Demand for Blood Pressure Monitoring & Measurement Instruments, According to a New Report by Global Industry Analysts, Inc. 4Health News:Announcing a New Title Pack from Pixel Film Studios, ProFont NoteBook for Final Cut Pro X 2Health News:Plastic Bird Spikes Now Come in 7 Colors to Blend in With Their Surroundings 2
... 2011)Approximately 10-20 percent of prostate cancer patients have a family ... that are used to evaluate the extent and aggressiveness of ... the Prostate Specific Antigen Level (PSA), Gleason score (GS) from ... However, men with a family history of prostate cancer have ...
... , WEDNESDAY, Oct. 5 (HealthDay News) -- Smokers have ... are more likely than men to suffer complications after a ... data on 3,588 patients admitted to the University of Michigan ... attack. About 24 percent of the patients were current smokers. ...
... A tracheostomy performed within the first seven days after a ... to a team of Penn State College of Medicine researchers. ... chance of surviving when admitted to the hospital. A ... neck directly into the trachea to allow unimpeded breathing. (A ...
... Therapeutics will be held from Nov. 12-16, 2011, at ... This unique conference combines the efforts of the American ... the European Organisation for the Research and Treatment of ... to focus exclusively on issues of drug development as ...
... New Tool That Helps Identify Prostate Cancer Patients with ... (October 4, 2011)After a prostate cancer patient receives radiation ... antigen, or PSA, in his blood. An increase in ... of the cancer,s return to the prostate. Fox Chase ...
... video games, already known to improve motor function in,recovering ... in intensive care units (ICU), new research from Johns,Hopkins ... Journal of Critical Care ,researchers studied the safety ... therapy in the ICU. "Patients admitted to our ...
Cached Medicine News:Health News:More aggressive treatment not necessary for men with a family history of prostate cancer 2Health News:Earlier tracheostomies result in better patient outcomes 2Health News:New tool helps identify prostate cancer patients with highest risk of death 2Health News:Practical play: Interactive video games appear valuable for ICU patients 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: